Anti-VEGF-therapy for pseudoxanthoma elasticum (case reports)
DOI: 10.32364/2311-7729-2023-23-3-8
A.D. Chuprov, S.M. Kim, E.A. Pidodniy, A.M. Iserkepova
Orenburg Branch of the S. Fyodorov Eye Microsurgery Federal State Institution, Orenburg, Russian Federation
Pseudoxanthoma elasticum (PXE), also known as Gröenblad-Strandberg syndrome, is a rare autosomal recessive disease affecting the skin, eyes, gastrointestinal tract, and cardiovascular system. The disease is caused by a defect in ABCC 6 (adenosine triphosphate-binding cassette, subfamily C, member 6) transporter involved in the homeostasis of serum pyrophosphate, the key inhibitor of ectopic calcification. Dysfunction or lack of ABCC 6 leads to a decrease in serum pyrophosphate levels and, as a result, ectopic calcification of soft connective tissue. Skin lesions in PXE are flat yellowish xanthomatous nodules of various shapes and sizes. The leading signs of eye disorder are angioid streaks and choroidal neovascularization (CNV). Progressive destruction of Bruch's membrane favors CNV, whereas macular neovascularization is the key reason for a reduction in central vision in PXE. Intravitreal injection of anti-VEGF medications is a promising treatment for CNV due to angioid bands. Ranibizumab is approved for CNV of various origins, including CNV due to angioid streaks. This paper addresses clinical observations illustrating the efficacy of anti-VEGF therapy for pseudoxanthoma elasticum.
Keywords: Gröenblad-Strandberg syndrome, angioid streaks, choroidal neovascularization, pseudoxanthoma elasticum, VEGF inhibitors.
For citation: Chuprov A.D., Kim S.M., Pidodniy E.A., Iserkepova A.M. Anti-VEGF-therapy for pseudoxanthoma elasticum (case reports). Russian Journal of Clinical Ophthalmology. 2023;23(3):157–163 (in Russ.). DOI: 10.32364/2311-7729-2023-23-3-8.
About the authors:
Aleksandr D. Chuprov — Dr. Sc. (Med.), Professor, Director, Orenburg Branch of the S. Fyodorov Eye Microsurgery Federal State Institution; 17, Salmyshskaya str., Orenburg, 460047, Russian Federation; ORCID iD 0000-0001-7011-4220.
Svetlana M. Kim — Head of the Department of Ophthalmology, Orenburg Branch of the S. Fyodorov Eye Microsurgery Federal State Institution; 17, Salmyshskaya str., Orenburg, 460047, Russian Federation; ORCID iD 0000-0003-2010-546X.
Ekaterina A. Pidodniy — ophthalmologist, Orenburg Branch of the S. Fyodorov Eye Microsurgery Federal State Institution; 17, Salmyshskaya str., Orenburg, 460047, Russian Federation; ORCID iD 0000-0001-9945-3293.
Aniya M. Iserkepova — ophthalmologist, Orenburg Branch of the S. Fyodorov Eye Microsurgery Federal State Institution; 17, Salmyshskaya str., Orenburg, 460047, Russian Federation; ORCID iD 0000-0001-9370-125X. Contact information: Svetlana M. Kim, e-mail: nauka@ofmntk.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 06.05.2022.
Revised 02.06.2022.
Accepted 28.06.2022.
2. Germain D.P. Pseudoxanthoma elasticum. Orphanet J Rare Dis. 2017;12(1):85. DOI: 10.1186/s13023-017-0639-8.
3. Le Saux O., Urban Z., Göring H.H. et al. Pseudoxanthoma elasticum maps to an 820-kb region of the p13.1 region of chromosome 16. Genomics. 1999;62(1):1–10. DOI: 10.1006/geno.1999.5925.
4. Gliem M., Finger R.P., Fimmers R. et al. Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review. Retina. 2013;33(7):1300–1314. DOI: 10.1097/IAE.0b013e3182914d2b.
5. Gliem M., Zaeytijd J.D., Finger R.P. et al. An update on the ocular phenotype in patients with pseudoxanthoma elasticum. Front Genet. 2013;4:14. DOI: 10.3389/fgene.2013.00014.
6. Edwards M., Lutty G.A. Bruch's Membrane and the Choroid in Age-Related Macular Degeneration. Adv Exp Med Biol. 2021;1256:89–119. DOI: 10.1007/978-3-030-66014-7_4.
7. Nakagawa S., Yamashiro K., Tsujikawa A. et al. The time course changes of choroidal neovascularization in angioid streaks. Retina. 2013;33(4):825–833. DOI: 10.1097/IAE.0b013e31826b0bbe.
8. Spaide R.F. Peau d'orange and angioid streaks: manifestations of Bruch membrane pathology. Retina. 2015;35(3):392–397. DOI: 10.1097/IAE.0000000000000420.
9. Mimoun G., Ebran J.M., Grenet T. et al. Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France. Graefes Arch Clin Exp Ophthalmol. 2017;255(8):1651–1660. DOI: 10.1007/s00417-017-3685-y.
10. Pece A., Avanza P., Galli L., Brancato R. Laser photocoagulation of choroidal neovascularization in angioid streaks. Retina. 1997;17(1):12–16. DOI: 10.1097/00006982-199701000-00003.
11. Fuisting B., Richard G. Transpupillary thermotherapy (TTT)–Review of the clinical indication spectrum. Medical Laser Application. 2010;25(4):214–222. DOI: 10.1016/j.mla.2010.07.002.
12. Aras C., Başerer T., Yolar M. et al. Two cases of choroidal neovascularization treated with transpupillary thermotherapy in angioid streaks. Retina. 2004;24(5):801–803. DOI: 10.1097/00006982-200410000-00020.
13. Ozdek S., Bozan E., Gürelik G., Hasanreisoglu B. Transpupillary thermotherapy for the treatment of choroidal neovascularization secondary to angioid streaks. Can J Ophthalmol. 2007;42(1):95–100. PMID: 17361248.
14. Shaikh S., Ruby A.J., Williams G.A. Photodynamic therapy using verteporfin for choroidal neovascularization in angioid streaks. Am J Ophthalmol. 2003;135(1):1–6. DOI: 10.1016/s0002-9394(02)01835-4.
15. Parolini B., Alkabes M., Baldi A., Pinackatt S. Visual recovery after autologous retinal pigment epithelium and choroidal patch in a patient with choroidal neovascularization secondary to angioid streaks: long-term results. Retin Cases Brief Rep. 2016;10(4):368–372. DOI: 10.1097/ICB.0000000000000265.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать